Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
About this item
Full title
Author / Creator
Publisher
Basel: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel: MDPI AG
Subjects
More information
Scope and Contents
Contents
Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels of circulating tumour cells (CTCs), the efficacy o...
Alternative Titles
Full title
Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a9212fe2fd9443cd854b6088bd96b44c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a9212fe2fd9443cd854b6088bd96b44c
Other Identifiers
ISSN
1999-4923
E-ISSN
1999-4923
DOI
10.3390/pharmaceutics13111879
